Johnson & Johnson (JNJ)
NYSE: JNJ · Real-Time Price · USD
163.08
-3.01 (-1.81%)
Feb 26, 2025, 4:00 PM EST - Market closed
Johnson & Johnson Revenue
In the year 2024, Johnson & Johnson had annual revenue of $88.82B with 4.30% growth. Johnson & Johnson had revenue of $22.52B in the quarter ending December 29, 2024, with 5.26% growth.
Revenue (ttm)
$88.82B
Revenue Growth
+4.30%
P/S Ratio
4.42
Revenue / Employee
$673,397
Employees
131,900
Market Cap
392.63B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 29, 2024 | 88.82B | 3.66B | 4.30% |
| Dec 31, 2023 | 85.16B | 5.17B | 6.46% |
| Jan 1, 2023 | 79.99B | 1.25B | 1.59% |
| Jan 2, 2022 | 78.74B | -3.84B | -4.65% |
| Jan 3, 2021 | 82.58B | 525.00M | 0.64% |
| Dec 29, 2019 | Pro | Pro | Pro |
| Dec 30, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Jan 1, 2017 | Pro | Pro | Pro |
| Jan 3, 2016 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 400.28B |
| Merck & Co. | 64.17B |
| AbbVie | 56.33B |
| AstraZeneca | 54.07B |
| Novartis AG | 51.72B |
| Eli Lilly and Company | 45.04B |
| Thermo Fisher Scientific | 42.88B |
| Abbott Laboratories | 41.95B |
JNJ News
- 1 day ago - INTRA-CELLULAR THERAPIES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Intra-Cellular Therapies, Inc. - ITCI - Business Wire
- 2 days ago - J&J sues Samsung Bioepis over contract breach for Stelara biosimilar - Reuters
- 5 days ago - TREMFYA® (guselkumab) subcutaneous (SC) induction data support potential to be the first and only in its class to offer the option of both intravenous and SC induction therapy in ulcerative colitis - PRNewsWire
- 5 days ago - Teva Pharma and Alvotech launch US biosimilar to J&J's Stelara - Reuters
- 7 days ago - AbbVie Vs. Johnson & Johnson: Graham Would Prefer The Consumer Healthcare Giant - Seeking Alpha
- 8 days ago - J&J begins crucial battle over $10 billion baby powder settlement - Reuters
- 8 days ago - Genmab: Positive 2025 Outlook, Johnson & Johnson's Decision Coming Soon - Seeking Alpha
- 8 days ago - Johnson & Johnson: Rich History Of Excellence Poised To Endure - Seeking Alpha